LONDON (Reuters) - A new diet pill from Orexigen Therapeutics Inc has been recommended for approval in Europe, the European Medicines Agency (EMA) said on Friday. The drug, known as Contrave in the United States, will be marketed as Mysimba in Europe. The medicine won U.S. approval in September and is a combination of the antidepressant bupropion and Orexigen's formulation of naltrexone, designed to prevent drug dependence. ...
via Health News Headlines - Yahoo News http://ift.tt/1r6KH9p
via Health News Headlines - Yahoo News http://ift.tt/1r6KH9p
No comments:
Post a Comment